, these studies have shown that blood levels possess a limited role in tumour diagnosis and are a relatively late indicator of disease in tumour monitoring (Finlay & McArdle, 1983) . However, more recently attention has been focused on the exploitation of the tumourassociated properties of CEA for radiolocalisation (Goldenberg et al., 1978a ) and targeting of tumoricidal agents (Rowland et al., 1982). Whether or not this potential will be realised in terms of clinical use will depend on several factors. We feel that the most important of these include the incidence of tumours which express CEA and the degree and significance of variation in antigen expression between patients' tumour cells. Antigenic heterogeneity has been observed (Jones, 1981) . Samples were available from the primary tumours of all 119 patients and from 81 of these who also had at least one histologically confirmed lymph node metastasis. Two hundred and fifty-seven lymph nodes were assessed; 210 contained metastases.
Summary The expression of carcinoembryonic antigen (CEA) in gastric malignancies has been assessed using a monoclonal antibody in an immunoperoxidase technique. Of 119 primary tumours examined, 92% reacted with the antibody. Metastases were available for 81 of the patients and 83% were CEA positive. A noteworthy observation was the detection of malignant cells in the lymph nodes of two patients, as a result of the presence of CEA, who were originally reported to be free of metastases. Of those patients whose primary tumours expressed CEA, 86% had at least one CEA positive metastasis. Two or more metastases were available from 60 of the patients and in 20% the secondaries were a mixture of positive and negative for CEA. Consequently, the CEA status of a single lesion does not enable confident prediction of expression in other metastases. In addition to variation between multiple lesions removed from the same patient phenotypic diversity of expression was observed between tumour cells of a given mass. Such distribution of the CEA detected by this monoclonal antibody may impose certain restrictions on its application. However, the high frequency of expression by gastric cancers indicate that it is a potentially useful antigen as a target for radiolocalisation or therapeutic agents.
Carcinoembryonic antigen (CEA) has been extensively investigated over the past 15 years. Much of the effort has been directed towards measurement of serum and tissue levels in many diseases, particularly gastrointestinal cancer. Generally (N.I.H. Concensus Statement, 1981) , these studies have shown that blood levels possess a limited role in tumour diagnosis and are a relatively late indicator of disease in tumour monitoring (Finlay & McArdle, 1983) . However, more recently attention has been focused on the exploitation of the tumourassociated properties of CEA for radiolocalisation (Goldenberg et al., 1978a) and targeting of tumoricidal agents (Rowland et al., 1982) . Whether or not this potential will be realised in terms of clinical use will depend on several factors. We feel that the most important of these include the incidence of tumours which express CEA and the degree and significance of variation in antigen expression between patients' tumour cells. Antigenic heterogeneity has been observed (Jones, 1981) . Samples were available from the primary tumours of all 119 patients and from 81 of these who also had at least one histologically confirmed lymph node metastasis. Two hundred and fifty-seven lymph nodes were assessed; 210 contained metastases.
Immunoperoxidase technique
The two-stage indirect immunoperoxidase technique as detailed by Ford et al. (1981) was used with the following modifications. The first antibody was a murine monoclonal anti-CEA (Li1-285-14)* raised to CEA by established procedures (Woodhouse, 1982 and Rowland et al., 1982) . It has been shown to lack reactivity with normal skin, brain, breast, lung, liver, bile duct, pancreas, kidney, prostate, testis, thyroid, spleen and lymph node by immunocytochemistry when used in a 1/1000 dilution of the unpurified ascitic fluid (as used in the remainder of this study). It binds to colonic and gastric tumours as well as 6/11 ductal mammary carcinomas. Some normal gastrointestinal and tonsillar epithelia also bind the antibody (Woodhouse, 1982; Gatter et al., 1982) . All foetal colonic tissues tested have been positive. There was no significant binding of this antibody to nonspecific cross-reacting antigen purified from human lung in an enzyme-linked immunosorbent assay (Woodhouse, 1982) .
The second antibody was a horseradish peroxidase conjugated rabbit antimouse immunoglobulin (Dakopatts). Each pair of sections was incubated with either a 1/1000 dilution of the first antibody or a 1/1000 dilution of P3-X63 Ag8 control ascitic fluid (Bethesda Research Laboratories) as a negative control and then with a 1/50 dilution of the conjugated second antibody. Each batch of sections processed included a pair of sections from a colonic carcinoma, known to express CEA, as a positive control.
Interpretation of staining Each section was assessed for the number of cells showing a positive reaction; intensity of stain was not assessed. The results were classified into 3 groups: one in which all cells were negative for CEA (-group): one in which it was considered that <5% of cells were positive (+ or weakly positive group) and one in which >5% of cells were considered to be positive (+ + or strongly positive group). Where more than one section of primary or more than one metastasis was assessed the patient was scored on the basis of the highest score achieved. Primary tumours (92.4%, Table I ) contained some CEA varying from a few cells to almost 100% in many cases, though even in these latter cases negative cells could almost always be found; 61.3% were strongly positive (+ +). Eighty-three percent of the patients with lymph node metastases were found to be positive, rather less than the primary tumours, but a greater proportion (68%) were found to be strongly positive (+ +). It was our impression that the metastatic deposits were generally more homogeneous in their CEA expression than the primary tumours. Variation of CEA expression in the lymph node metastases of an individual patient. Samples were available from 60 patients who had 2 or more metastases (range 2-13 mean 3.1) ( Table III) . The pattern of CEA expression was entirely consistent i.e. all the metastases were strongly positive (+ +) or all were weakly positive (+) or all were negative for CEA in 70%. In a further 10% all the metastases were positive but a mixture of weakly (+) and strongly (+ +) positive staining coexisted. However an important finding was that 20% of patients had a mixture of negatively and positively, in some cases strongly positively, staining metastases. 
Discussion
The overall rate of positivity in this study was found to be 92% for primary tumours and 83% for metastases. It is difficult to make a direct comparison of these results with previously published studies since to our knowledge there have been no others in which a monoclonal antibody has been used and most of those using polyclonal antisera have examined relatively small numbers of gastric tumours. One exception to this was an immunofluorescence study of 150 gastric carcinomas (Lee et al., 1978) in which 62% were found to be "to a great extent histologically positive." Also using an immunofluorescence technique Ejeckam et al. (1979) found that 90% of 29 carcinomas were positive. Using an immunoperoxidase technique CEA expression occurred in all of 18 (Skinner & Whitehead, 1982) and 7 (Wagener et al., 1981) gastric carcinomas. The latter authors also noted that the staining was either patchy or restricted to some single positive cells. Goldenberg et al. (1978b) , have reported that 5 of 14 gastric carcinomas were positive, a significantly lower proportion than the other studies. The high proportion reported here may be due to differences in sensitivity or specificity, i.e. our test system may be more sensitive or our antibody recognises a sub-species of CEA distinct from that recognised by other workers. Heterogeneity of CEA expression within lesions has been previously reported in stomach tumours (Ejeckam et al., 1979) . We have confirmed this and have also noted important differences of CEA expression between separate lesions taken from an individual patient.
There are several possible reasons for these observations. It is well known that gastric tumours are histologically heterogeneous (Day, 1981) and ability to express CEA may be a biochemical equivalent of the morphological heterogeneity. Diversity of several phenotypic characteristics seems to be a feature of many neoplasms (Fidler & Hart, 1982) and it has been suggested that antigen markers could be used as an indicator of aggressive behaviour or metastatic capacity. However, our results do not support the notion that CEA identifies a subpopulation of cells with greater metastatic potential since the 81 patients with metastases had 91% positive primaries and produced 83% positive metastases, a difference which is even less if only the strongly positive are considered, giving 67% and 68% respectively -the expected result if CEA and metastatic potential are unrelated. Alternatively it has been shown that CEA production by some cultured cells is dependent upon the phase of cell growth (Drewinko & Yang, 1976) and consequently CEA expression may be related to the stage of the cell cycle at which the cells were sampled; even in our cases with near total staining a few cells did not stain. The possibility must also be considered that monoclonal antibodies may reveal a greater degree of heterogeneity than polyclonal antibodies as a result of a restriction of epitope recognition (Rogers et al., 1981 and Primus et al., 1983) . Thus, 11-285-14 may detect a species of CEA which is expressed by a certain fraction of the cells and does not necessarily preclude expression of different species of CEA by other cells of heterogeneous tumour. The implications of heterogeneous CEA expression for immunodiagnosis and therapy will depend upon the technique and agents employed. For radiolocalisation and targeted therapy the presence of negative cells in a tumour may not matter provided that enough target antigen is present to provide a tumour to normal tissue differential. However, we have identified a population of 20% of patients with mixed positive and negative metastatic tumours in whom failure of localisation would be expected.
Using a monoclonal antibody we have demonstrated that CEA or a subspecies of CEA is expressed by the majority of gastric carcinomas and shows phenotypic heterogeneity within and between different primary and metastatic tumours. These results reveal that CEA is not an ideal target antigen for gastric cancer. Still, there is as yet no evidence of an antigen associated with this disease which does not suffer from the same disadvantages. Consequently, we feel that the role of CEA as a target for delivery of localising and therapeutic agents deserves further investigation, possibly using a combination of different antibodies to overcome the problem of heterogeneity.
